摘要
目的观察帕利哌酮缓释片对急性期精神分裂症患者临床症状及认知功能的影响。方法选取本院2015年1月至2017年1月收治的急性期精神分裂症患者64例，根据随机数字表法分为观察组及对照组，各32例。对照组使用氟哌啶醇治疗，观察组使用帕利哌酮缓释片治疗；治疗4个月后，对比两组患者精神症状及认知功能改善情况。结果随着治疗时间的增加，两组精神症状均有明显改善，且观察组改善情况显著优于对照组，差异有统计学意义（P〈0．05）；两组治疗期间认知功能评分均随着治疗时间的延长而逐渐降升高，但观察组各治疗时段分值显著高于对照组，差异有统计学意义（均P〈0．05）；两组治疗期间均无明显不良反应发生，均耐受。结论帕利哌酮缓释片治疗急性期精神分裂症疗效确切，患者治疗后精神症状明显缓解，认知功能显著改善，患者治疗期间无明显不良反应发生，安全可靠。
Objective To observe the effect of paliperidone extended-release tablets on clinical symptoms and cognitive function in patients with acute schizophrenia. Methods 64 patients with acute schizophrenia treated at our hospital from January, 2015 to January, 2017 were selected and were divided into an observation group and a control group by random number table, 32 cases for each group. The control group were treated with haloperidol and the observation group with paliperidone extended-release tablets. After four- month treatment, the improvement of mental symptoms and cognitive function were compared between the two groups. Results As treatment time prolonged, the mental symptoms of the two groups significantly improved, and the observation group was better than the control group （P 〈 0.05）. As treatment time prolonged, the scores of cognitive function in the two groups gradually increased, and the scores of the observation group at each time point were higher than those of the control group （P 〈 0.05）. No significant adverse reactions occurred in the two groups during treatment, with well tolerance. Conclusion Paliperidone extended-release tablets in the treatment of acute schizophrenia is effective and can significantly relieve the patients＇ mental symptoms and improve cognitive function and causes no significant adverse reactions during treatment and is safe and reliable.
出处
《国际医药卫生导报》
2018年第2期239-241,共3页
International Medicine and Health Guidance News
关键词
急性期精神分裂症
帕利哌酮缓释片
临床症状
认知功能
Acute schizophrenia
Paliperidone extended-release tablets
Clinical symptoms
Cognitivefunction
